B-BIC Collaborative

megaphone
Coaching
stopwatch
Rolling Applications
non-dilutive
Non-Dilutive

Proposals Received

Member Institution

pie-member-institutions

Clinical Area

pie-clinical-area

Technology Type

pie-technology-type

Awards Granted

PI
Institution
Clinical Area
Technology Type
Jonathan Thon
A Biomimetic Human Platelet Bioreactor
BWH
Blood
Therapeutic Device
Seemantini Nadkarni
A Blood Coagulation Sensor for Point of Care Use
MGH
Blood
Diagnostic Device
Eric Gale
A Manganese Alternative To Gadolinium for MRI Contrast
MGH
Blood
Diagnostic Device
Mei Wu
A Prototype Laser Device for Treatment of Thrombocytoenia
MGH
Blood
Therapeutic Device
Daniel Irimia
Accurate Sepsis Diagnostic Using a Neutrophil Microfluidic Device
MGH
Blood
Diagnostic Device
Gary Gilbert
Activated Platelet Time: An Improved Factor VIII Assay
Harvard
Blood
Other
Brian Polizzotti
Advanced Development of Intravenous Oxygen Microparticles
BCH
Lung
Therapeutic Device
Aditya Kaza
Confocal Microscopy for Intraoperative Discrimination of Cardiac Conduction Tissue
BCH
Heart
Therapeutic Device
Ali Khademhosseini
Developing a Biocompatible Elastic Sealant
BWH
Lung
Therapeutic Device
Nikolay Vasilyev
Development of an Implantable Intracardiac Soft Robotic Right Ventricular Ejection Device
BWH
Heart
Therapeutic Device
Warren Zapol
Electric Nitric Oxide Generation for Medical Purposes
MGH
Lung
Therapeutic Device
John Connor
Elimination of Pathogenic IgE in Cystic Fibrosis
BU/BMC
Lung
Biologic Drug
Xin Zhang
Impedance-Based, Continuous Hematocrit Monitoring in the Trauma Population
BU/BMC
Blood
Diagnostic Device
Ehud Schmidt
Intracardiac MRI Ablation-Monitoring Catheter
BWH
Heart
Diagnostic Device
Anders Naar
MicroRNA Antisense Therapeutics in Cardiometabolic Diseases
MGH
Heart
Biologic Drug
Elazer Edelman
Minimally Invasive Tissue Engineering Therapies for Acute Airway Injury
MIT
Lung
Therapeutic Device
Paul Yu
Molecular Imaging of Dysregulated Angiogenesis in Pulmonary Arterial Hypertension
BWH
Lung
Diagnostic Device
Ehud Schmidt
MRI-Compatible Voltage Device Tracking for Multimodality Electrophysiology
BWH
Heart
Therapeutic Device
Edgar Milford
Novel Antibody Targeting Approach for the Treatment of Idiopathic Pulmonary Fibrosis
BWH
Lung
Biologic Drug
Karin Hoffmeister
Novel Approaches for Platelet Storage
BWH
Blood
Other
David Milan
Novel Treatment for Long QT Syndrome
MGH
Heart
Small Molecule Drug
Jonghan Kim
Pharmacokinetics of Multifunctional Nanochelators in Iron Overload Disorders
NEU
Blood
Small Molecule Drug
Samuel Patz
Portable MR Device for the Pulmonary ICU
BWH
Lung
Diagnostic Device
Benjamin Matthews
PR1P, an Inhaled Novel Short Peptide for Emphysema
BCH
Lung
Small Molecule Drug
Matthew Spite
Pro-Resolving Micro-/Nano-Particles to Improve Vascular Patency
BWH
Blood
Therapeutic Device
Gabriel Gruionu
Rapid Perfusion Catheter
MGH
Blood
Therapeutic Device
Bruce Bean
Silencing Airway Nociceptors for Treatment of Cough and Airway Inflammation
HMS
Lung
Small Molecule Drug
Michael Sweeney
SQPAN
BWH
Heart
Therapeutic Device
Pamela Silver
Targeting Erythropoietin-Based Therapeutics
Harvard
Blood
Biologic Drug
Jason Fiering
Therapeutic Apheresis by Microfluidic Acoustic Separation
Draper
Blood
Therapeutic Device
Leo Tsai
Variable Stiffness Microcatheter for Navigation of Tortuous Vessels
BIDMC
Other
Therapeutic Device

Funding Programs

Pilot Grants

Pilot awards support projects  to demonstrate proof of concept, such as prototype development, or reproducibility experiments in different model systems. Pilot awards provide up to $88,750 total cost. (Indirect costs are provided at the applicant institution’s negotiated Federal rate.) Pilot projects are expected to be completed within one year.

DRIVE Grants

DRIVE  awards are provided as investments in early-stage technologies that have the potential for commercial translation within two years. DRIVE awards provide up to $350,000 total cost to support proof-of-value studies. (Indirect costs are provided  at the applicant institution’s negotiated Federal rate.)

Areas of Interest

B-BIC will select early stage technologies that address unmet medical needs or offer great scientific opportunities with either immediate commercial potential or otherwise present compelling reasons for continued development. B-BIC is currently focused on innovative devices, diagnostics, and therapeutics related to heart, lung, blood, and sleep disorders. Program priority areas include, but are not limited to, the following:

Cardiovascular Diseases

Heart failure, atherothrombosis, myocardial infarction, hypertension, atrial fibrillation along with other atrial and ventricular arrhythmias, sudden cardiac death, adult and pediatric congenital heart disease, cardiovascular complications of diabetes and obesity, acquired valve disease, cardiomyopathies, and peripheral vascular diseases.

Lung Diseases and Sleep Disorders

Asthma, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, cystic fibrosis, respiratory neurobiology, sleep-disordered breathing, critical care and acute lung injury, developmental biology and pediatric pulmonary diseases, immunologic and fibrotic pulmonary disease, rare lung disorders, pulmonary vascular disease, and pulmonary complications of AIDS and tuberculosis.

Blood Diseases and Resources

Sickle cell disease (SCD), the thalassemias, Fanconi anemia, Diamond-Blackfan anemia and other bone marrow failure syndromes, iron metabolism, fetal hemoglobin production, white blood cell disorders, myeloproliferative and myelodysplastic syndromes, hematopoietic stem cell transplantation and novel cell-based therapies, transfusion medicine (red blood cells, platelets, and plasma) and blood banking including technologies to store and process blood, thrombosis and hemostatic disorders including but not limited to idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), hemophilia, and coagulation factor deficiencies and disorders.

The Process

circle-one

Eligibility

  • Faculty from the B-BIC member institutions are eligible to apply.
  • For-profit entities are eligible to apply as collaborators with Principal Investigators at member institutions.
  • The proposed work must support the advancement of technology that is owned by a B-BIC member institution.
circle-two

Budget Considerations

  • Applications to the Pilot program may request up to $88,750 direct.
  • Applications to the DRIVE program may request up to $350,000 direct.
  • For awards supported with Federal dollars, indirect costs are provided at the applicant institution’s negotiated Federal rate.
  • The current NIH salary cap must be applied to personnel costs.
    B-BIC supports the advancement of technology towards commercial development. Funds are not awarded for the purchase of equipment, travel, or publication costs except under unusual circumstances.
  • DRIVE awards will be released in accordance with milestone and tranche plans included with the application.
circle-three

Deadlines and Proposal Review

  • Pre-proposals may be submitted anytime throughout the year. There is no set deadline for submissions.
  • A subset of applicants who submit pre-proposals will be invited to develop full proposals.
  • Full proposals are reviewed on a rolling basis by members of the B-BIC External Selection Committee, including representatives from the local life sciences and venture capital communities. Full proposals are also reviewed by our Federal Partners, including representatives from the USPTO, FDA, CMS, and payor/provider organizations. To minimize the time between full proposal submission and funding decision, the optimal times to submit full proposal are mid-January, mid-April, mid-July, and mid-October.

Format

All pre-proposals and full proposals must be submitted using the online application system at b-bic.fluidreview.com.

All required supporting documents, including the B-BIC budget form, compliance, form, NIH biosketches, and institutional authorization  must be uploaded into the online application system.

All text material must be in a readable font (at least Arial 10 point), and margins must be at least 0.5 inches.

B-BIC is funded by the NIH/NHLBI under award U54HL119145 and through the institutional support provided by our member institutions.